Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608
| Autor: | Lange, Thoralf *, Krahl, Rainer *, von Grünhagen, Ulrich *, Al-Ali, Haifa Kathrin *, Andreas, Schwarzer *, Jentsch-Ulrich, Kathleen *, Spohn, Claudia *, Lakner, Volker *, Assmann, Michael *, Junghanss, Christian *, Pfirrmann, Markus *, Gil, Arthur *, Hehlmann, Rüdiger, Deininger, Michael W., Niederwieser, Dietger |
|---|---|
| Zdroj: | In Blood 8 December 2017 130 Supplement 1:1615-1615 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|